
Capricor Therapeutics CAPR
$ 26.83
-3.94%
Quarterly report 2025-Q3
added 11-10-2025
Capricor Therapeutics Total Assets 2011-2026 | CAPR
Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.Main categories of assets
Current assets (used within one year):
- Cash and cash equivalents
- Accounts receivable (amounts owed by customers)
- Inventory of goods, raw materials, and supplies
- Short-term investments
- Fixed assets (buildings, machinery, equipment)
- Intangible assets (brands, patents, software)
- Long-term investments
- Goodwill (reputational value from mergers)
Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.
Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.
Annual Total Assets Capricor Therapeutics
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 58.7 M | 50.1 M | 41.3 M | 34.6 M | 11.1 M | 9.25 M | 16.3 M | 18.7 M | 16.1 M | 13.6 M | 5.54 M | 227 K | 1.37 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 58.7 M | 227 K | 21.3 M |
Quarterly Total Assets Capricor Therapeutics
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126 M | 134 M | 154 M | 170 M | 93 M | 38.3 M | 49.4 M | 58.7 M | 37.2 M | 46 M | 53.9 M | 50.1 M | 53.9 M | 58.1 M | 64.9 M | 41.3 M | 43.1 M | 39.9 M | 43.5 M | 34.6 M | 34.6 M | 34.6 M | 34.6 M | 11.1 M | 11.1 M | 11.1 M | 11.1 M | 9.25 M | 9.25 M | 9.25 M | 9.25 M | 16.3 M | 16.3 M | 16.3 M | 16.3 M | 18.7 M | 18.7 M | 18.7 M | 18.7 M | 16.1 M | 16.1 M | 16.1 M | 16.1 M | 13.6 M | 13.6 M | 13.6 M | 13.6 M | 5.54 M | 5.54 M | 5.54 M | 5.54 M | 5.42 M | 227 K | 227 K | 227 K | 1.37 M | 1.37 M | 1.37 M | 1.37 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 170 M | 227 K | 31.7 M |
Total Assets of other stocks in the Biotechnology industry
| Issuer | Total Assets | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
2.03 B | - | 2.43 % | $ 254 M | ||
|
Acer Therapeutics
ACER
|
11.6 M | - | 2.71 % | $ 14 M | ||
|
I-Mab
IMAB
|
6.33 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
18.1 B | - | - | $ 40.3 B | ||
|
AgeX Therapeutics
AGE
|
12 M | - | -10.17 % | $ 12.2 K | ||
|
Biophytis SA
BPTS
|
12 M | - | -13.47 % | $ 169 M | ||
|
Aeglea BioTherapeutics
AGLE
|
778 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
66.7 M | - | - | $ 26.5 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
15.2 M | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
14.8 M | - | -18.52 % | $ 27.3 M | ||
|
ARCA biopharma
ABIO
|
396 M | - | 1052.0 % | $ 415 M | ||
|
Acorda Therapeutics
ACOR
|
109 M | - | -24.86 % | $ 820 K | ||
|
Acasti Pharma
ACST
|
72 M | - | 4.01 % | $ 150 M | ||
|
Adverum Biotechnologies
ADVM
|
180 M | - | - | $ 86.2 M | ||
|
Институт стволовых клеток человека
ISKJ
|
1.51 B | - | - | - | ||
|
AIkido Pharma
AIKI
|
47.1 M | - | 1.93 % | $ 17.4 M | ||
|
Akero Therapeutics
AKRO
|
826 M | - | - | $ 3.67 B | ||
|
Akouos
AKUS
|
279 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
302 M | - | -0.23 % | $ 916 M | ||
|
Allena Pharmaceuticals
ALNA
|
34.8 M | - | 3.16 % | $ 1.9 M | ||
|
Aileron Therapeutics
ALRN
|
62.2 M | - | 10.36 % | $ 9.8 M | ||
|
AlloVir
ALVR
|
119 M | - | 4.14 % | $ 49.1 M | ||
|
Alpine Immune Sciences
ALPN
|
287 M | - | - | $ 2.17 B | ||
|
Aeterna Zentaris
AEZS
|
35.1 M | - | 5.93 % | $ 314 M | ||
|
Ampio Pharmaceuticals
AMPE
|
5.74 M | - | -11.43 % | $ 502 K | ||
|
Applied Molecular Transport
AMTI
|
107 M | - | - | $ 10.1 M | ||
|
Aravive
ARAV
|
62.2 M | - | -13.39 % | $ 1.45 M | ||
|
Aptose Biosciences
APTO
|
10.1 M | - | -45.71 % | $ 1.2 M | ||
|
Aptinyx
APTX
|
66.7 M | - | -39.0 % | $ 4.57 M | ||
|
Athira Pharma
ATHA
|
58.8 M | - | - | $ 269 M | ||
|
Aridis Pharmaceuticals
ARDS
|
14.7 M | - | 17.91 % | $ 11.1 M | ||
|
Arena Pharmaceuticals
ARNA
|
785 M | - | -6.81 % | $ 3.04 B | ||
|
CureVac N.V.
CVAC
|
1.16 B | - | - | $ 867 M | ||
|
Avenue Therapeutics
ATXI
|
2.67 M | - | -52.27 % | $ 4.45 M | ||
|
Athersys
ATHX
|
60.2 M | - | 3.77 % | $ 22.4 M | ||
|
Axcella Health
AXLA
|
18.9 M | - | -16.42 % | $ 249 M | ||
|
AstraZeneca PLC
AZN
|
114 B | - | - | $ 96.9 B | ||
|
AVEO Pharmaceuticals
AVEO
|
105 M | - | - | $ 521 M | ||
|
Atreca
BCEL
|
155 M | - | -11.76 % | $ 5.79 M | ||
|
AVROBIO
AVRO
|
101 M | - | 1083.1 % | $ 745 M | ||
|
Agenus
AGEN
|
314 M | $ 3.27 | -1.8 % | $ 1.17 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.77 M | - | - | $ 7.46 M | ||
|
Agios Pharmaceuticals
AGIO
|
1.3 B | $ 28.72 | -5.0 % | $ 1.66 B | ||
|
bluebird bio
BLUE
|
619 M | - | - | $ 546 M | ||
|
Brickell Biotech
BBI
|
11.6 M | - | -5.38 % | $ 6.06 M | ||
|
Advaxis
ADXS
|
16.6 M | - | -9.65 % | $ 45.9 M | ||
|
Завод ДИОД
DIOD
|
1.4 B | - | - | - | ||
|
Фармсинтез
LIFE
|
2.05 B | - | - | - | ||
|
Baudax Bio
BXRX
|
10 M | - | 0.59 % | $ 63 K | ||
|
Calithera Biosciences
CALA
|
64.8 M | - | -10.95 % | $ 876 K |